Literature DB >> 27691992

EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS: RESPONSE.

Alison Florence Smith1, Andrew Sutton1, Bethany Shinkins1.   

Abstract

As strong advocates and adopters of early cost-effectiveness modeling for test evaluation, we were excited to see the recent article "The Early Bird Catches the Worm: Early Cost-Effectiveness Analysis of New Medical Tests," in which Buisman and colleagues present a succinct and generalizable framework for conducting this type of analysis. The authors have done an excellent job in identifying and summarizing the key components of this methodology, as well as highlighting fundamental differences between early analyses versus the traditional late-stage approach. As the number of medical tests coming to market continues to grow, there is an ever growing need to develop rigorous methodology in this area, and we commend the authors for this timely work.

Mesh:

Year:  2016        PMID: 27691992     DOI: 10.1017/S026646231600043X

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  1 in total

1.  An early analysis of the cost-effectiveness of a diagnostic classifier for risk stratification of haematuria patients (DCRSHP) compared to flexible cystoscopy in the diagnosis of bladder cancer.

Authors:  Andrew J Sutton; John V Lamont; R Mark Evans; Kate Williamson; Declan O'Rourke; Brian Duggan; Gurdeep S Sagoo; Cherith N Reid; Mark W Ruddock
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.